DFO
ADMA icon

Duquesne Family Office’s ADMA Biologics ADMA Stock Holding History

Duquesne Family Office’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Buy
2,784,110
+1,238,500
+80% +$11.3M 0.45% 45
2026
Q1 		$13.9M Buy
1,545,610
+1,293,410
+513% +$20.4M 0.41% 49
2025
Q4 		$4.6M Buy
+252,200
New +$4.25M 0.1% 58

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Duquesne Family Office's ADMA Position: Q2 2026 in Review

Duquesne Family Office increased its ADMA Biologics (ADMA) stake by 80% in Q2 2026, buying an estimated $11.3M and bringing the position to 2,784,110 shares worth $23.3M. The position accounts for 0.45% of the portfolio, ranked #45.

Duquesne Family Office first reported a position in ADMA in Q4 2025 and has held it in 3 quarters since. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Duquesne Family Office held 2,784,110 shares of ADMA Biologics worth $23.3M as of Q2 2026.
  • Duquesne Family Office bought 1,238,500 ADMA Biologics shares in Q2 2026, an estimated $11.3M.
  • ADMA Biologics made up 0.45% of Duquesne Family Office's portfolio in Q2 2026, its #45 holding.
  • Duquesne Family Office first reported a position in ADMA Biologics in Q4 2025 and has held it in 3 quarters since.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.